Skip to main content
  • Saved

made a Post

Population Pharmacokinetics of Belantamab Mafodotin, a BCMA-targeting Agent in Patients with Relapsed/Refractory Multiple Myeloma - PubMed

Population Pharmacokinetics of Belantamab Mafodotin, a BCMA-targeting Agent in Patients with Relapsed/Refractory Multiple Myeloma - PubMed

Source :

https://pubmed.ncbi.nlm.nih.gov/34076364/

Belantamab mafodotin (belamaf) is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA). Nonlinear mixed-effects models were developed to characterize the population pharmacokinetics (PopPK) of ADC, total monoclonal antibody (mAb), and cysteine-maleimidocaproyl-MMAF (cys-mcMMAF) after 0.03-4.6 mg/kg dosing every 3 weeks in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM) (DREAMM-1, n=73; DREAMM-2, n=218).